Related Experiment Videos
Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells
David Steiner1, Noga Brunicki, Bruce R Blazar
1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Experimental Hematology
|January 18, 2006
Summary
Third-party regulatory T (Treg) cells can enhance bone marrow (BM) allograft engraftment, similar to donor-type Treg cells. This finding supports the development of an "off-the-shelf" Treg cell bank for improved cell therapy.
Area of Science:
- Immunology
- Transplantation Immunology
- Cell Therapy
Background:
- Regulatory T (Treg) cells, specifically CD4(+)CD25(+), show potential in controlling graft-versus-host disease (GVHD) and graft rejection after allogeneic bone marrow transplantation (BMT).
- Investigating the efficacy of third-party Treg cells offers an alternative to donor-type Treg cells for facilitating BM allografting.
Purpose of the Study:
- To compare the potential of third-party Treg cells versus donor-type Treg cells in facilitating bone marrow (BM) allografting.
- To assess the feasibility of using third-party Treg cells for cell therapy applications.
Main Methods:
- A mouse model of T cell-mediated BM allograft rejection was utilized.
- Lethally irradiated mice received T cell-depleted BM allografts.
- Graft rejection was induced by host-type T cells, and Treg cells were added to the BM allograft to assess their facilitating activity.
Main Results:
- Both naive and ex vivo-expanded third-party Treg cells effectively enhanced the engraftment of T cell-depleted BM allografts.
- The in vitro and in vivo reactivity of third-party Treg cells was comparable to that of donor-type Treg cells.
Conclusions:
- Third-party Treg cells demonstrate efficacy in facilitating BM allografting, similar to donor-type Treg cells.
- Utilizing third-party Treg cells allows for the pre-preparation of an "off-the-shelf" cell bank, simplifying quality control and logistics for cell therapy.